CLOS
INZY

Compagnie Lombard Odier SCmA’s Inozyme Pharma INZY Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,525
Closed -$50K – 654
2021
Q1 		$50K Hold
2,525
– – ﹤0.01% 511
2020
Q4 		$52K Hold
2,525
– – ﹤0.01% 433
2020
Q3 		$66K Buy
+2,525
New +$62.7K ﹤0.01% 370

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Compagnie Lombard Odier SCmA's INZY Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of Inozyme Pharma (INZY) in Q2 2021, closing a stake of 2,525 shares — an estimated $50K sold.

Compagnie Lombard Odier SCmA first reported a position in INZY in Q3 2020 and held it in 3 quarters. The position peaked at $66K in Q3 2020. 50 funds tracked by Wall St. Rank hold INZY as of Q2 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Inozyme Pharma position as of Q2 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 2,525 Inozyme Pharma shares in Q2 2021, an estimated $50K.
  • Compagnie Lombard Odier SCmA first reported a position in Inozyme Pharma in Q3 2020 and held it in 3 quarters.
  • Compagnie Lombard Odier SCmA's Inozyme Pharma position peaked at $66K in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.